Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors
Pathogens · 24.09.2024 · 13 (10) · 825
DOI: 10.3390/pathogens13100825 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathogens, online erschienen am 24.09.2024. Verfasst von Marcel Arruda Diogo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, COVID-19 Drug Treatment, Coronavirus Papain-Like Proteases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível.
Abstract (Originalsprache)
SARS-CoV-2 is a spherical, positive-sense, single-stranded RNA virus with a large genome, responsible for encoding both structural proteins, vital for the viral particle’s architecture, and non-structural proteins, critical for the virus’s replication cycle. Among the non-structural proteins, two cysteine proteases emerge as promising molecular targets for the design of new antiviral compounds. The main protease (Mpro) is a homodimeric enzyme that plays a pivotal role in the formation of the viral replication–transcription complex, associated with the papain-like protease (PLpro), a cysteine protease that modulates host immune signaling by reversing post-translational modifications of ubiquitin and interferon-stimulated gene 15 (ISG15) in host cells. Due to the importance of these molecular targets for the design and development of novel anti-SARS-CoV-2 drugs, the purpose of this review is to address aspects related to the structure, mechanism of action and strategies for the design of inhibitors capable of targeting the Mpro and PLpro. Examples of covalent and non-covalent inhibitors that are currently being evaluated in preclinical and clinical studies or already approved for therapy will be also discussed to show the advances in medicinal chemistry in the search for new molecules to treat COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.
ORCID-Profile: Marcel Arruda Diogo, Renata Barbosa de Oliveira
Förderung
- Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
- Coordenação de Aperfeiçoamento de Pessoal de Nível
- Federal University of Minas Gerais (UFMG)
Zitieren
APA
Diogo, M. A., Cabral, A. G. T., & de Oliveira, R. B. (2024). Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors. Pathogens, 13(10), 825. https://doi.org/10.3390/pathogens13100825
Vancouver
Diogo MA, Cabral AGT, de Oliveira RB. Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors. Pathogens. 2024;13(10):825. doi:10.3390/pathogens13100825
BibTeX
@article{Diogo2024,
author = {Diogo, Marcel Arruda and Cabral, Augusto Gomes Teixeira and de Oliveira, Renata Barbosa},
title = {Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors},
journal = {Pathogens},
year = {2024},
volume = {13},
number = {10},
pages = {825},
doi = {10.3390/pathogens13100825}
}
EUVIMED